Press releases Back to newsroom Press releases Pherecydes Pharma selected for the French Tech Health20 program’s 2023 class See more ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies See more Pherecydes Pharma successfully completes €3.1 million capital increase See more Pherecydes Pharma launches a capital increase for c. €3m to continue its clinical development program in phage therapy See more Pherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus See more Pherecydes Pharma obtains AAC Early Access Program approval from the ANSM for its anti-Staphylococcus aureus phages See more Pherecydes Pharma announces its 2020 annual financial results and confirms its 2021 outlook See more A preclinical trial demonstrates the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia See more Pherecydes Pharma strengthens its Management Committee: recruitment of Céline Breda as Director of Industrial Operations See more Pherecydes Pharma Announces its Financial Agenda for 2021 See more Pherecydes Pharma’s phage production project (PhagoPROD) featured in the European Commission’s CORDIS magazine See more Pherecydes Pharma raises €8.7M ($10.3M) - 16/01/18 see more
